Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 PRODUCTION CONSUMPTION ANALYSIS
4.3.1 INTRODUCTION
4.3.2 PRODUCTION SIDE ANALYSIS
4.3.2.1 PHOTOSENSITIZER MANUFACTURING
4.3.2.2 DEVICE MANUFACTURING
4.3.2.3 RESEARCH AND INNOVATION
4.3.3 CONSUMPTION SIDE ANALYSIS
4.3.3.1 CLINICAL APPLICATION
4.3.3.2 TREATMENT VOLUMES AND TRENDS
4.3.3.3 DOSAGE AND PROTOCOLS
4.3.4 PRODUCTION–CONSUMPTION DYNAMICS
4.3.4.1 SUPPLY CONSTRAINTS
4.3.4.2 REGIONAL OVERVIEW
4.3.4.3 FUTURE OUTLOOK
4.3.5 CONCLUSION
4.4 COST ANALYSIS BREAKDOWN
4.4.1 INTRODUCTION
4.4.2 DIRECT MEDICAL COSTS
4.4.2.1 COST OF PHOTOSENSITIZERS
4.4.2.2 LIGHT DELIVERY SYSTEMS
4.4.2.3 HEALTHCARE FACILITY CHARGES
4.4.3 INDIRECT COSTS
4.4.3.1 PATIENT-RELATED EXPENSES
4.4.3.2 POST-TREATMENT MONITORING
4.4.4 COMPARATIVE COST-EFFECTIVENESS
4.4.5 REIMBURSEMENT AND INSURANCE IMPACT
4.4.6 REGIONAL COST VARIATIONS
4.4.7 FUTURE COST TRENDS AND REDUCTION STRATEGIES
4.4.7.1 TECHNOLOGICAL ADVANCEMENTS
4.4.7.2 HEALTHCARE EFFICIENCY INITIATIVES
4.4.8 CONCLUSION
4.5 TECHNOLOGICAL ADVANCEMENTS
4.5.1 INTRODUCTION
4.5.2 NEXT-GENERATION PHOTOSENSITIZERS
4.5.3 ADVANCEMENTS IN LIGHT DELIVERY SYSTEMS
4.5.4 NANOTECHNOLOGY-ENABLED DELIVERY
4.5.5 COMBINATION THERAPIES AND IMMUNOMODULATION
4.5.6 DIGITAL INTEGRATION AND TREATMENT PLANNING
4.5.7 RECENT TRENDS AND OUTLOOK
4.5.8 CONCLUSION
4.6 VALUE CHAIN ANALYSIS
4.6.1 INTRODUCTION
4.6.2 RESEARCH & DEVELOPMENT
4.6.2.1 DISCOVERY OF PHOTOSENSITIZERS
4.6.2.2 DEVELOPMENT OF LIGHT DELIVERY SYSTEMS
4.6.2.3 CLINICAL TRIALS AND REGULATORY APPROVALS
4.6.3 MANUFACTURING
4.6.3.1 PRODUCTION OF PHOTOSENSITIZERS
4.6.3.2 FABRICATION OF LIGHT DELIVERY DEVICES
4.6.4 DISTRIBUTION & LOGISTICS
4.6.4.1 SUPPLY CHAIN MANAGEMENT
4.6.4.2 INTERNATIONAL TRADE AND MARKET ACCESS
4.6.5 CLINICAL APPLICATION
4.6.5.1 INTEGRATION INTO TREATMENT PROTOCOLS
4.6.5.2 TRAINING AND EDUCATION
4.6.6 POST-TREATMENT MONITORING & SUPPORT
4.6.6.1 FOLLOW-UP CARE
4.6.6.2 PATIENT SUPPORT SERVICES
4.6.7 TECHNOLOGICAL ADVANCEMENTS INFLUENCING THE PDT VALUE CHAIN
4.6.7.1 NANOTECHNOLOGY IN PDT
4.6.7.2 ARTIFICIAL INTELLIGENCE AND IMAGING
4.6.7.3 PERSONALIZED MEDICINE
4.6.8 CONCLUSION
4.7 VENDOR SELECTION CRITERIA
4.7.1 INTRODUCTION
4.7.2 CORE SELECTION CRITERIA
4.7.2.1 REGULATORY COMPLIANCE
4.7.2.2 CLINICAL EVIDENCE AND RESEARCH SUPPORT
4.7.2.3 TECHNICAL PERFORMANCE AND DEVICE COMPATIBILITY
4.7.2.4 QUALITY MANAGEMENT AND MANUFACTURING STANDARDS
4.7.2.5 SERVICE, TRAINING, AND AFTER-SALES SUPPORT
4.7.2.6 SUPPLY CHAIN RELIABILITY
4.7.3 RECENT TRENDS IN VENDOR SELECTION
4.7.4 RISK FACTORS AND VULNERABILITIES
4.7.5 KEY PERFORMANCE INDICATORS
4.7.6 STRATEGIC RECOMMENDATIONS
4.7.7 CONCLUSION
4.8 PATENT ANALYSIS
4.8.1 PATENT QUALITY AND STRENGTH
4.8.2 PATENT FAMILIES
4.8.3 LICENSING AND COLLABORATIONS
4.8.4 REGIONAL PATENT LANDSCAPE
4.8.5 IP STRATEGY AND MANAGEMENT
4.9 SUPPLY CHAIN ANALYSIS
4.9.1 OVERVIEW
4.9.2 LOGISTIC COST SCENARIO
4.9.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS
4.9.4 CONCLUSION
4.1 INDUSTRY ECOSYSTEM ANALYSIS
4.10.1 INTRODUCTION
4.10.2 ECOSYSTEM ARCHITECTURE — KEY ACTORS AND ROLES
4.10.2.1 CORE TECHNOLOGY PROVIDERS
4.10.2.2 ENABLING INSTITUTIONS
4.10.3 VALUE CHAIN AND FUNCTIONAL FLOWS
4.10.3.1 RESEARCH AND DISCOVERY
4.10.3.2 CLINICAL DEVELOPMENT AND REGULATORY VALIDATION
4.10.3.3 MANUFACTURING AND QUALITY ASSURANCE
4.10.3.4 DISTRIBUTION, PROCUREMENT AND CLINICAL ADOPTION
4.10.4 MARKET ENABLERS AND INFRASTRUCTURE
4.10.4.1 SCIENTIFIC AND REGULATORY ENABLERS
4.10.4.2 REIMBURSEMENT AND HEALTH-ECONOMICS INFRASTRUCTURE
4.10.4.3 MANUFACTURING AND SUPPLY-CHAIN CAPACITY
4.10.5 INTERDEPENDENCIES AND STRATEGIC PARTNERSHIPS
4.10.5.1 ACADEMIA-INDUSTRY TECHNOLOGY TRANSFER
4.10.5.2 VERTICAL INTEGRATION AND CONTRACT MANUFACTURING
4.10.5.3 CLINICAL NETWORKS AND KOL ECOSYSTEMS
4.10.6 RISKS, CONSTRAINTS AND SYSTEMIC VULNERABILITIES
4.10.6.1 REGULATORY COMPLEXITY FOR COMBINED PRODUCTS
4.10.6.2 SUPPLY-CHAIN CONCENTRATION AND MATERIAL RISK
4.10.6.3 EVIDENCE AND REIMBURSEMENT UNCERTAINTY
4.10.6.4 CLINICAL OPERATIONAL BARRIERS
4.10.7 STRATEGIC IMPLICATIONS AND RECOMMENDATIONS
4.10.8 OUTLOOK — EVOLUTION OF THE ECOSYSTEM
4.10.9 CONCLUSION
4.11 INNOVATION TRACKER AND STRATEGIC ANALYSIS
4.11.1 INTRODUCTION
4.11.2 RECENT TECHNOLOGICAL INNOVATIONS
4.11.2.1 ADVANCED PHOTOSENSITIZERS
4.11.2.2 OXYGEN-SELF-SUFFICIENT PLATFORMS
4.11.2.3 ALTERNATIVE ACTIVATION MODALITIES
4.11.2.4 SMART NANOPLATFORMS
4.11.2.5 NOVEL CHEMICAL STRUCTURES
4.11.3 STRATEGIC INNOVATIONS IN DELIVERY SYSTEMS
4.11.3.1 LIGHT DELIVERY DEVICES
4.11.3.2 COMBINATION THERAPIES
4.11.3.3 IMAGING INTEGRATION
4.11.4 KEY CHALLENGES
4.11.5 STRATEGIC THEMES
4.11.6 STRATEGIC IMPLICATIONS FOR MARKET PLAYERS
4.11.7 RECOMMENDATIONS
4.11.8 OUTLOOK AND STRATEGIC RISKS
4.11.9 CONCLUSION
4.12 PRICING ANALYSIS
4.12.1 INTRODUCTION
4.12.2 COMPONENTS OF THE TOTAL TREATMENT PRICE
4.12.2.1 PHOTOSENSITIZING AGENT (DRUG) COSTS
4.12.2.2 DEVICE CAPITAL AND MAINTENANCE COST
4.12.2.3 CONSUMABLES AND PROCEDURAL OVERHEAD
4.12.2.4 INDIRECT AND DOWNSTREAM COSTS
4.12.3 PRICING MODELS AND APPROACHES
4.12.3.1 COST-PLUS AND MARKUP MODELS
4.12.3.2 VALUE-BASED AND OUTCOMES-LINKED PRICING
4.12.3.3 BUNDLED PAYMENTS AND PROCEDURAL TARIFFS
4.12.3.4 SUBSCRIPTION AND MANAGED-SERVICE MODELS FOR DEVICES
4.12.4 REIMBURSEMENT LANDSCAPE
4.12.4.1 UNITED STATES: MEDICARE AND COMMERCIAL PAYERS
4.12.4.2 EUROPE AND OTHER HIGH-INCOME MARKETS
4.12.4.3 EMERGING MARKETS AND OUT-OF-POCKET DYNAMICS
4.12.5 REGIONAL PRICE DIFFERENTIALS AND DRIVERS
4.12.5.1 MANUFACTURING FOOTPRINT AND SUPPLY-CHAIN EFFECTS
4.12.5.2 REGULATORY BURDEN AND MARKET ACCESS TIMELINES
4.12.5.3 CLINICAL PRACTICE PATTERNS AND REIMBURSEMENT POLICY
4.12.6 PRICE SENSITIVITY, ACCESS, AND EQUITY
4.12.6.1 PRICE ELASTICITY IN HOSPITAL PROCUREMENT
4.12.6.2 PATIENT ACCESS AND SOCIOECONOMIC BARRIERS
4.12.7 COMPETITIVE & STRATEGIC PRICING IMPLICATIONS
4.12.7.1 DIFFERENTIATION-BASED PREMIUM PRICING
4.12.7.2 PENETRATION PRICING AND VOLUME STRATEGIES
4.12.7.3 MANAGED ENTRY AGREEMENTS AND OUTCOMES GUARANTEES
4.12.8 RECOMMENDATIONS FOR STAKEHOLDERS
4.12.8.1 FOR MANUFACTURERS
4.12.8.2 FOR PROVIDERS AND HOSPITAL SYSTEMS
4.12.8.3 FOR PAYERS AND POLICYMAKERS
4.12.9 RISKS, UNCERTAINTIES, AND FUTURE PRICE PRESSURES
4.12.10 CONCLUSION
5 TARIFFS & IMPACT ON THE MARKET
5.1 INTRODUCTION
5.2 TARIFF LANDSCAPE RELEVANT TO PDT PRODUCTS
5.2.1 CATEGORIES OF TRADE EXPOSURE
5.2.2 RECENT AND EMERGING TARIFF MEASURES OF CONSEQUENCE
5.3 DIRECT COST IMPACTS
5.3.1 INCREASED LANDED COSTS AND MARGIN COMPRESSION
5.3.2 PRICE VOLATILITY AND PROCUREMENT BUDGETING
5.4 SUPPLY-CHAIN & MANUFACTURING IMPLICATIONS
5.4.1 SUPPLIER DIVERSIFICATION AND RESHORING INCENTIVES
5.4.2 SOURCING OF HIGH-VALUE NANOMATERIALS AND COMPONENTS
5.4.3 REGULATORY AND QUALIFICATION COSTS FOR NEW SUPPLIERS
5.5 CLINICAL ACCESS, PRICING & REIMBURSEMENT EFFECTS
5.5.1 ACCESS RISK FOR PATIENTS AND PROVIDERS
5.5.2 REIMBURSEMENT PRESSURE AND HEALTH-ECONOMIC ASSESSMENTS
5.6 R&D, INNOVATION & COMPETITIVE IMPLICATIONS
5.6.1 DISRUPTION OF RESEARCH SUPPLIES AND COLLABORATION FLOWS
5.6.2 STRATEGIC REPOSITIONING AND COMPETITIVE ADVANTAGE
5.7 POLICY, COMPLIANCE & REGULATORY CONSIDERATIONS
5.7.1 USE OF WTO AND PREFERENTIAL TRADE RULES
5.7.2 TARIFF MITIGATION TOOLS AND ADVOCACY
5.8 RECOMMENDATIONS FOR STAKEHOLDERS
5.9 CONCLUSION
6 REGULATION COVERAGE
6.1 PRODUCT CODES
6.1.1 CERTIFIED STANDARDS
6.1.2 SAFETY STANDARDS
6.1.3 MATERIAL HANDLING & STORAGE
6.1.4 TRANSPORT & PRECAUTIONS
6.1.5 HAZARD IDENTIFICATION
6.1.6 CONCLUSION
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CANCER
7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE THERAPIES
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN PHOTOSENSITIZERS AND DEVICES
7.1.4 EXPANDING RESEARCH AND CLINICAL DEVELOPMENT PIPELINE
7.2 RESTRAINTS
7.2.1 LIMITED DEPTH OF LIGHT PENETRATION
7.2.2 HIGH COST OF TREATMENT
7.3 OPPORTUNITIES
7.3.1 INTEGRATION WITH OTHER CANCER THERAPIES
7.3.2 DEVELOPMENT OF NOVEL PHOTOSENSITIZERS
7.3.3 M&A AND PARTNERSHIPS WITH ONCOLOGY DEVICE/LASER FIRMS AND PHARMA
7.4 CHALLENGES
7.4.1 TUMOR HYPOXIA AS A BIOLOGICAL BARRIER TO PHOTODYNAMIC THERAPY EFFICACY
7.4.2 COMPETITION FROM ALTERNATIVE TREATMENTS
8 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 PHOTOSENSITIZER DRUGS
8.3 PHOTODYNAMIC THERAPY DEVICES
9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION
9.1 OVERVIEW
9.2 SKIN & CUTANEOUS ONCOLOGY
9.3 HEAD & NECK
9.4 ESOPHAGAL
9.5 LUNG
9.6 BLADDER
9.7 CERVICAL
9.8 PROSTATE
10 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY
10.1 OVERVIEW
10.2 STANDALONE THERAPY
10.3 ADJUNCTIVE THERAPY
10.4 PALLIATION THERAPY
10.5 OTHERS
11 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE
11.1 OVERVIEW
11.2 EXTERNAL BEAM
11.3 INTRACAVITARY (ENDOSCOPIC) DELIVERY
11.4 INTERSTITIAL (INTERNAL) DELIVERY
11.5 OTHERS
12 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE
12.1 OVERVIEW
12.2 EARLY-STAGE CANCER
12.3 LATE-STAGE CANCER
13 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS
13.1 OVERVIEW
13.2 GERIATRIC
13.3 ADULTS
13.4 PEDIATRIC
14 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DERMATOLOGY & SKIN-CANCER CLINICS
14.4 AMBULATORY SURGICAL CENTERS (ASCS)
14.5 ACADEMIC & RESEARCH INSTITUTES
14.6 OTHERS
15 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 THIRD PARTY DISTRIBUTORS
15.4 ONLINE
15.5 OTHERS
16 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 NOVERTIS AG
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 GALDERMA S. A.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 PHOTOCURE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 ADVANZ PHARMA CORP.
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENT
19.5 AMERISOURCE BERGEN CORPORATION
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 BIOFRONTERA AG
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 BIOLITEC HOLDING GMBH & CO KG
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 CARDINAL HEALTH
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 HEMERION THERAPEUTICS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 IMPACT BIOTECH
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 INOVA
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 LUMIBIRD
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 LUZITIN
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 MCKESSON
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MODULIGHT CORPORATION
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 ONCOLUX INC (FORMERLY LUMEDA INC.)
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SUN PHARMACEUTICAL INDUSTRIES LTD
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENT
19.18 THERALASE TECHNOLOGIES INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 4 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 5 NORTH AMERICA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 6 NORTH AMERICA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 NORTH AMERICA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 NORTH AMERICA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 10 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 13 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 16 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 19 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA STANDALONE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA ADJUNCTIVE THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA PALLIATION THERAPY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA EXTERNAL BEAM IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA INTRACAVITARY (ENDOSCOPIC) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA INTERSTITIAL (INTERNAL) DELIVERY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA EARLY-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA LATE-STAGE CANCER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA GERIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA ADULTS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA PEDIATRIC IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA DERMATOLOGY & SKIN-CANCER CLINICS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA AMBULATORY SURGICAL CENTERS (ASCS) IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH AMERICA ACADEMIC & RESEARCH INSTITUTES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA DIRECT TENDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA ONLINE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA OTHERS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 69 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 71 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 NORTH AMERICA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 NORTH AMERICA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 75 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH AMERICA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 77 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 NORTH AMERICA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 NORTH AMERICA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 81 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 NORTH AMERICA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 83 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 84 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 85 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 86 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 87 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 88 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 NORTH AMERICA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 90 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 91 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 U.S. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 U.S. PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 94 U.S. PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 U.S. LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 U.S. ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 98 U.S. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 U.S. SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 100 U.S. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 U.S. HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 102 U.S. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 U.S. ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 104 U.S. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 U.S. LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 106 U.S. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 U.S. BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 108 U.S. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 U.S. CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 110 U.S. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 U.S. PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 112 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 113 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 114 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 115 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 116 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 117 U.S. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 U.S. HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 119 U.S. CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 120 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 CANADA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 CANADA PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 123 CANADA PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 CANADA LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 CANADA ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 127 CANADA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 CANADA SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 129 CANADA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 CANADA HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 131 CANADA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 CANADA ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 133 CANADA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 CANADA LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 135 CANADA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 CANADA BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 137 CANADA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 CANADA CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 139 CANADA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 CANADA PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 141 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 142 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 143 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 144 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 145 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 146 CANADA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 CANADA HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 148 CANADA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 149 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 MEXICO PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 MEXICO PHOTOSENSITIZER DRUGS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY FORMULATION, 2018-2032 (USD THOUSAND)
TABLE 152 MEXICO PHOTODYNAMIC THERAPY DEVICES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 MEXICO LIGHT DELIVERY SYSTEMS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 MEXICO ACCESSORIES & CONSUMABLES IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032 (USD THOUSAND)
TABLE 156 MEXICO SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 MEXICO SKIN & CUTANEOUS ONCOLOGY IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 158 MEXICO HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 MEXICO HEAD & NECK IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 160 MEXICO ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 MEXICO ESOPHAGAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 162 MEXICO LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 MEXICO LUNG IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 164 MEXICO BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 MEXICO BLADDER IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 166 MEXICO CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 MEXICO CERVICAL IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 168 MEXICO PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 MEXICO PROSTATE IN CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 170 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 171 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 172 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032 (USD THOUSAND)
TABLE 173 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD THOUSAND)
TABLE 174 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 175 MEXICO HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 MEXICO HOSPITALS IN CANCER PHOTODYNAMIC THERAPY MARKET, BY SIZE, 2018-2032 (USD THOUSAND)
TABLE 177 MEXICO CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: NORTH AMERICA VS REGIONAL ANALYSIS
FIGURE 5 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: SEGMENTATION
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 STRATEGIC DECISIONS
FIGURE 12 TWO SEGMENTS COMPRISE THE NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE (2024)
FIGURE 13 INCREASING PREVALENCE OF CANCER ACROSS GLOBE EXPECTED TO DRIVE THE NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 14 PHOTOSENSITIZER DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET IN 2025 & 2032
FIGURE 15 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET-MARKET OVERVIEW
FIGURE 16 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024
FIGURE 17 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2024
FIGURE 18 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032
FIGURE 19 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PRODUCT TYPE, 2018-2032
FIGURE 20 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024
FIGURE 21 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2024
FIGURE 22 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032
FIGURE 23 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY CANCER INDICATION, 2018-2032
FIGURE 24 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024
FIGURE 25 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2024
FIGURE 26 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032
FIGURE 27 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY THERAPY MODALITY, 2018-2032
FIGURE 28 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024
FIGURE 29 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2024
FIGURE 30 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032
FIGURE 31 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PROCEDURE TECHNIQUE, 2018-2032
FIGURE 32 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024
FIGURE 33 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2024
FIGURE 34 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032
FIGURE 35 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISEASE STAGE, 2018-2032
FIGURE 36 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2024
FIGURE 37 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032
FIGURE 38 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032
FIGURE 39 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY PATIENT DEMOGRAPHICS, 2018-2032
FIGURE 40 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024
FIGURE 41 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2024
FIGURE 42 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032
FIGURE 43 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY END USER, 2018-2032
FIGURE 44 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024
FIGURE 45 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2024
FIGURE 46 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032
FIGURE 47 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2018-2032
FIGURE 48 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: SNAPSHOT (2024)
FIGURE 49 NORTH AMERICA CANCER PHOTODYNAMIC THERAPY MARKET: COMPANY SHARE 2024 (%)
